I want to get continuous structured data on emerging pharmaceutical drug pricing, formulary changes, and utilization management criteria from competitor payer websites and pharmaceutical manufacturer regulatory filings.
A shared demo template. Read-only preview of what would be monitored in a real pilot.
Click to explore each section
This is a real demo!
Click to explore each section.
Jsonify Configuration Template
Goal
I want to get continuous structured data on emergi...
Gain continuous insights on drug pricing and formulary shifts — automated intelligence that outpaces manual research efforts
12 website or app sources
The Jsonify AI will open these automatically to explore and find your information
9
data columns
12
dashboard widgets
3
integrations
1
notification
Data sources are the websites and apps where information will be collected from. These can be changed or expanded at any time. This is turned into data rows.
Sample data preview. This is synthetic test data generated to illustrate the structure. Real data from your sources will be populated during the pilot. This data powers the dashboard widgets.
| id | Source | Drug | NDC | Price | Original Price | Formulary Status | Utilization Management | Last Updated | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 1 |
|
Tresiba (insulin degludec) | 0006-0687-01 | $389.00 | $422.00 | Preferred | Prior Authorization for new starts; Quantity Limit 1 vial/month | Feb 2, 2026 | ||
| 2 |
|
Leqvio (inclisiran) | 0007-1223-10 | $3,200.00 | $3,400.00 | Non-Preferred | Step Therapy after statin + ezetimibe; Prior Auth required | Feb 3, 2026 | ||
| 3 |
|
Zeposia (ozanimod) | 0012-3456-88 | $3,100.00 | $3,250.00 | Tier 4 | Prior Authorization; Initial Rx limit 1 month | Feb 1, 2026 | ||
| 4 |
|
Ozempic (semaglutide) 1.0 mg | 0034-5678-20 | $899.99 | $1,049.99 | Not Covered (cash alternative) | Quantity Limit 1 pen/28 days; Savings coupons available | Feb 4, 2026 | ||
| 5 |
|
Xanax (alprazolam) | 0045-1122-11 | $12.50 | $15.00 | Preferred Generic | Generic substitution allowed; Quantity Limit 60 tablets/30 days | Feb 3, 2026 | ||
| 6 |
|
BNT162b4 (mRNA COVID booster) | 0055-9900-01 | $0.00 | $0.00 | Not Listed (investigational) | Clinical trial only; Not for routine formularies | Feb 2, 2026 | ||
| 7 |
|
Keytruda (pembrolizumab) | 0066-2233-77 | $12,450.00 | $12,950.00 | Major Therapeutic Class - Restricted | Prior Authorization; Oncology pathway review required | Feb 1, 2026 | ||
| 8 |
|
Humira (adalimumab) biosimilar | 0077-4411-02 | $5,200.00 | $6,100.00 | Preferred Biosimilar | Step Therapy preferred biosimilar before originator; PA for dosage >40 mg q2w | Feb 4, 2026 | ||
| 9 |
|
Aduhelm (aducanumab) | 0088-5566-33 | $11,600.00 | $13,000.00 | Excluded | Restricted to registry-enrolled patients; Prior Auth + cognitive assessment required | Feb 3, 2026 | ||
| 10 |
|
Eliquis (apixaban) | 0099-6677-10 | $480.00 | $530.00 | Preferred Brand | PA for patients with mechanical heart valves; Quantity Limit 30 tablets/30 days | Feb 2, 2026 | ||
| 11 |
|
Sotagliflozin | 0100-7788-55 | $375.00 | $425.00 | Tier 3 | Prior Authorization; Must have documented T1D with inadequate control | Feb 4, 2026 | ||
| 12 |
|
Tirzepatide (new GLP-1/GIP) | 0111-8899-66 | $1,250.00 | $1,350.00 | Non-Preferred Brand | Step Therapy requires metformin + GLP-1 trial; PA for BMI <30 | Feb 3, 2026 | ||
| 13 |
|
Remdesivir (Veklury) | 0122-9900-21 | $2,800.00 | $3,150.00 | Covered Under Medical Benefit | Facility-level authorization; Limited to hospitalized patients | Feb 2, 2026 | ||
| 14 |
|
Zynteglo (gene therapy) | 0133-1010-01 | $2,800,000.00 | $2,900,000.00 | Specialty/Rare | Outcomes-based contract recommended; Prior Authorization and registry enrollment | Feb 3, 2026 | ||
| 15 |
|
Dupixent (dupilumab) | 0144-2020-44 | $3,980.00 | $4,200.00 | Tier 4 (Specialty) | Prior Authorization; Step therapy for atopic dermatitis alternatives | Feb 1, 2026 | ||
| 16 |
|
Synthroid (levothyroxine) 50 mcg | 0155-3030-50 | $18.99 | $24.99 | Preferred Generic | Generic substitution allowed; No prior authorization | Feb 4, 2026 | ||
| 17 |
|
Imbruvica (ibrutinib) | 0166-4040-60 | $9,600.00 | $10,200.00 | Restricted Oncology | PA with documented diagnosis and prior chemo failure; Quantity Limit per cycle | Feb 3, 2026 | ||
| 18 |
|
Nivolumab combo (trial) | 0177-5050-02 | $0.00 | $0.00 | Investigational | Clinical trial only; Not eligible for formulary coverage | Feb 2, 2026 | ||
| 19 |
|
Trikafta (elexacaftor/tezacaftor/ivacaftor) | 0188-6060-77 | $340,000.00 | $350,000.00 | Specialty - Limited Access | PA with genotype confirmation; Prior Authorization and specialty pharmacy dispensing | Feb 1, 2026 | ||
| 20 |
|
Xeljanz (tofacitinib) | 0199-7070-11 | $2,100.00 | $2,350.00 | Non-Preferred | Prior Authorization; TB screening required before initiation | Feb 4, 2026 | ||
| 21 |
|
Adagrasib (KRAS inhibitor) | 0200-8181-33 | $21,500.00 | $23,000.00 | Restricted Oncology | PA with molecular test confirmation; Limited to labeled indications | Feb 3, 2026 | ||
| 22 |
|
Metformin ER 1000 mg | 0211-9191-99 | $14.00 | $18.00 | Preferred Generic | No PA; Quantity Limit 90 tablets/90 days | Feb 2, 2026 | ||
| 23 |
|
Vyvgart (efgartigimod) | 0222-0202-20 | $8,750.00 | $9,200.00 | Specialty | PA; Must document autoantibody-mediated disease and prior therapies | Feb 4, 2026 | ||
| 24 |
|
BCMA CAR-T autologous therapy | 0233-1313-01 | $465,000.00 | $495,000.00 | Hospital Only / Excluded from pharmacy benefit | Center-of-excellence referral; Outcomes-based reimbursement suggested | Feb 3, 2026 | ||
| 25 |
|
Fluad Quadrivalent (seasonal influenza) | 0244-2424-08 | $22.00 | $28.00 | Covered Vaccine | No PA for adults 65+; Quantity limits per season | Feb 2, 2026 | ||
| 26 |
|
Nirsevimab (RSV monoclonal) | 0255-3535-05 | $445.00 | $495.00 | Preferred for infants | Age/weight-based dosing restrictions; Prior Authorization for high-risk infants | Feb 3, 2026 | ||
| 27 |
|
Biktarvy (bictegravir/emtricitabine/tenofovir) | 0266-4646-30 | $1,400.00 | $1,575.00 | Tier 2 | PA for HIV-2 or resistance; Quantity limit 30 tablets/30 days | Feb 1, 2026 | ||
| 28 |
|
Albuterol HFA inhaler | 0277-5757-01 | $34.99 | $39.99 | Preferred Brand | Allowed OTC alternatives; Quantity Limit 1 inhaler/30 days | Feb 4, 2026 | ||
| 29 |
|
Zolgensma (onasemnogene abeparvovec) | 0288-6868-01 | $2,150,000.00 | $2,200,000.00 | Rare/Specialty | Single-dose gene therapy; PA, registry enrollment, outcomes-based contract | Feb 3, 2026 | ||
| Looking for more? Great news − this is just a small sample. Jsonify production workflows process anywhere from tens of thousands to millions of real data rows per run! | ||||||||||
From
–
To
Filters
Loading filters...
Loading filters...
Total Products Tracked
1,203
total products tracked
8%
Formulary Changes by Category
Drug Utilization Trends
Average Price Change (%)
4.5%
average price change
0.5%
Competitor Payers with Most Changes
Pricing Sources Breakdown
Average Price Over Time
Recent Drug Pricing Updates
| Source | Product | Price | Change | Date |
|---|---|---|---|---|
|
|
Aspirin | $9.99 |
|
2026-01-30 |
|
|
Ibuprofen | $11.50 | -1.0% | 2026-01-29 |
|
|
Metformin | $15.00 |
|
2026-01-28 |
|
|
Lisinopril | $20.00 |
|
2026-01-25 |
|
|
Atorvastatin | $25.30 | -0.5% | 2026-01-27 |
|
|
Simvastatin | $12.75 |
|
2026-01-26 |
|
|
Levothyroxine | $18.20 | -2.0% | 2026-01-31 |
Key Insights on Drug Pricing
Recent data shows a 15% increase in average drug prices across leading pharmaceutical brands.
Formulary changes are occurring more frequently, with a 30% rise in updates reported on payer websites compared to last quarter.
A significant trend indicates that utilization management criteria are tightening, particularly for specialty medications, with 40% more restrictions noted in the past month.
Top 10 Drugs by Price Increase
Utilization Management Criteria Summary
| Source | Product | Price | Change | Date |
|---|---|---|---|---|
|
|
Drug A | $150.00 | -5% | 2026-01-15 |
|
|
Drug B | $200.00 | 0% | 2026-01-20 |
|
|
Drug C | $350.00 | +10% | 2026-01-18 |
|
|
Drug D | $120.00 | -3% | 2026-01-25 |
|
|
Drug E | $180.00 | +8% | 2026-01-30 |
|
|
Drug F | $220.00 | -2% | 2026-01-21 |
|
|
Drug G | $300.00 | +15% | 2026-01-28 |
|
|
Drug H | $175.00 | 0% | 2026-01-27 |
Formulary Changes Over Time
Structured data feeds are included — we're happy to help with API integration and automation.
JSON
Loading...
CSV
Loading...
Looking for more? Great news − this is just a small sample. Typically, our commercial customers process tens of thousands to millions of data points per task!
Radar continuously monitors your selected web sources and alerts you the moment something changes.
+7
Recent change
Price Change Detected
Yesterday
Drug ABC is now $100 (+$20)
Recent change
New Listing Appears
Yesterday
Drug XYZ now available on formulary
Recent change
Availability Change
3h ago
Drug DEF is now unavailable
Recent change
Coverage Gap Identified
5m ago
Drug GHI missing from current formulary
Recent change
Utilization Management Update
1h ago
Drug JKL criteria updated
Data connections determine where the collected data will be delivered. You can add, remove, or change connections at any time.
Scroll down to see more